自然来源的临床有效分子用于预防或治疗肥胖症
Gladys Maribel Hidalgo-Lozada1, Angelica Villarruel-López2, Karla Nuño3
1Institute of Science and Technology for Health Innovation, Guadalajara 44770, Mexico.
International journal of molecular sciences
|March 13, 2024
概括
天然生物活性化合物为肥胖管理提供了有希望的替代品. 这些化合物在补充剂和食物中发现,显示出治疗肥胖和相关疾病的潜力,副作用比传统疗法少.
科学领域:
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 全球肥胖和相关并发症的增加构成了重大的健康挑战.
- 现有的肥胖疗法往往具有不良影响,高成本和有限的可访问性.
- 天然生物活性化合物正在成为可行的治疗替代品.
研究的目的:
- 为肥胖症提供基于自然的治疗选择提供全面的审查.
- 探索各种生物活性化合物的分子机制和临床证据.
- 为未来的研究和肥胖管理中的临床应用提供见解.
主要方法:
- 对生物活性化合物的临床研究和分子研究的系统文献综述.
- 分析与肥胖相关的信号通路和基因表达.
- 对诸如甲基-3-酸盐,白醇和黄素等化合物的证据的评估.
主要成果:
- 生物活性化合物与内分泌,神经和胃肠系统相互作用.
- 机制包括调节饥饿腹,激活棕色脂肪组织,改善胰岛素敏感性.
- 诸如表甲基-3-酸,酸,复星和柏柏林等化合物显示出显著的治疗潜力.
结论:
- 基于自然的化合物为肥胖治疗提供了一个有希望的,可能更安全的,更容易获得的方法.
- 对分子,遗传和生理基础的进一步研究是有必要的.
- 这些发现支持将生物活性化合物纳入未来的肥胖临床实践.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


